NCT02255357View on ClinicalTrials.gov

Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 14, 2018

Study Completion Date

February 14, 2018

Conditions
Cocaine Dependence
Interventions
DRUG

Placebo

Solution containing only the excipients of the original solution without Oxytocin.

DRUG

Intranasal Oxytocin

solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm

Trial Locations (2)

10032

Substance Treatment and Research Service (STARS), Manhattan

10045

Divison on Substance Abuse - Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT02255357 - Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients. | Biotech Hunter | Biotech Hunter